Strategic Objectives

The main strategic objectives of this project include:


  • Performing ambitious, but relatively short-term research within the Consortium of eight world-class R&D groups, well beyond conventional approaches, to realize a highly novel ‘NA-NOSE’ that has the potential for highly sensitive detection of cancer biomarkers in a simple, inexpensive and non-invasive manner.

  • Establishing interaction and communication between the different disciplines involved in LCAOS, and between academia and industry. By sharing expertise and knowledge (including via an exchange of personnel) between academia, clinical institutions, SMEs, and diagnostics companies, the newly integrated ‘NA-NOSE’ will be produced for clinical-track applications by the end of the project. The industrial participants, in addition to participating in the research, will also play a role in shaping the academic research through their feedback to the approaches developed. The academic partners will provide access to the industrial partners to test clinical samples and advanced characterization methods.

  • Facilitating the swift transfer of clinical and academic research results, as well as hardware and software directly to SMEs/companies specialized in commercializing devices and methods. SMEs will be a crucial role in achieving this objective, which also includes validation and benchmarking of the novel ‘NA-NOSE’ at clinical sites, and performing comparisons with other diagnostic and screening tools.

  • Given the multi-disciplinary nature of the LCAOS Consortium, the partners will be able to provide multi-disciplinary training to researchers and students. The partners will exploit this opportunity by exchanging personnel for extended periods of time, as well as organizing workshops and 2 mini-conferences (summer-school) throughout the four-year effort.

  • To make most effective use of resources, a lab-track and a clinical-track will run in parallel. In the lab-track, a prototype ‘NA-NOSE’ will be developed and tested. In the clinical-track a more professionalized version of the ‘NA-NOSE’ will be tested in clinical environments to carry out screening of high-risk population, monitoring of therapy progress and use of the device to direct surgery.